Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19312645 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | August 2025 | January 2026 | Allow | 4 | 1 | 0 | No | No |
| 19312755 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | August 2025 | January 2026 | Allow | 4 | 1 | 0 | No | No |
| 19312786 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | August 2025 | January 2026 | Allow | 4 | 1 | 0 | No | No |
| 19313046 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | August 2025 | February 2026 | Allow | 6 | 1 | 0 | No | No |
| 19313010 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | August 2025 | February 2026 | Allow | 6 | 1 | 0 | No | No |
| 19312656 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | August 2025 | December 2025 | Allow | 3 | 0 | 0 | No | No |
| 19238613 | METHOD FOR FORMING AN N-SUBSTITUTED PYRROLE FROM A HEXADIONE WITH A JUICE CATALYST | June 2025 | August 2025 | Allow | 2 | 1 | 0 | No | No |
| 19225802 | NON-COVALENT MODIFIERS OF AKT1 AND USES THEREOF | June 2025 | December 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19215938 | 7-METHYL INDOLE ANALOGS AND DOSAGE FORMS CONTAINING THE SAME | May 2025 | August 2025 | Allow | 3 | 1 | 0 | No | No |
| 19187874 | JUICE-BASED SYNTHETIC METHOD FOR PYRROLES | April 2025 | July 2025 | Allow | 3 | 1 | 0 | No | No |
| 19187847 | PYRROLE SYNTHESIS METHOD USING JUICE CATALYST | April 2025 | July 2025 | Allow | 3 | 1 | 0 | No | No |
| 19187833 | GREEN SYNTHESIS METHOD FOR FORMING SUBSTITUTED PYRROLES | April 2025 | June 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19187339 | SYNTHESIS OF N-SUBSTITUTED PYRROLES BY GREEN CATALYST | April 2025 | June 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19041219 | CCR5 INHIBITOR | January 2025 | May 2025 | Allow | 3 | 1 | 0 | No | No |
| 19003381 | ORGANOSELENIUM BENZIMIDAZOLE COMPOUNDS FOR TREATING CANCER | December 2024 | March 2025 | Allow | 2 | 0 | 0 | No | No |
| 18973849 | LEFLUTROZOLE COMPOSITIONS OF MATTER AND PROCESSES FOR PREPARATION | December 2024 | March 2025 | Allow | 3 | 0 | 0 | No | No |
| 18968441 | MIXED SEROTONIN 5-HT2A/2C RECEPTOR AGONISTS AND METHODS FOR TREATING PAIN AND DEPRESSION | December 2024 | March 2025 | Allow | 3 | 1 | 1 | No | No |
| 18939592 | CYTOTOXIC TREATMENT OF CANCER CELLS | November 2024 | January 2025 | Allow | 2 | 1 | 0 | No | No |
| 18799676 | METHOD FOR CONTACTING CANCER CELLS WITH ANTITUMOR AGENT AND APOPTOTIC INDUCER | August 2024 | October 2024 | Allow | 2 | 1 | 0 | No | No |
| 18748709 | TREATMENT OF COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA | June 2024 | September 2025 | Abandon | 15 | 0 | 1 | No | No |
| 18745664 | PARP INHIBITORS FOR TREATING CANCER AND ASTHMA | June 2024 | April 2025 | Allow | 10 | 1 | 0 | Yes | No |
| 18741888 | Neuroplastogens and Non-Hallucinogenic Serotonin 5-HT2A Receptor Modulators | June 2024 | December 2024 | Allow | 6 | 1 | 0 | No | No |
| 18731154 | CFTR REGULATORS AND METHODS OF USE THEREOF | May 2024 | April 2025 | Allow | 10 | 0 | 0 | No | No |
| 18671182 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | May 2024 | December 2024 | Allow | 6 | 0 | 0 | No | No |
| 18661337 | 3-(2-(1,3-DIOXOISOINDOLIN-2-YL)ETHYL)-5-(2-HYDROXY-5-NITROBENZYLIDENE)THIAZOLIDINE-2,4-DIONE AS A POTENTIAL ANTITUMOR AND APOPTOTIC INDUCER | May 2024 | July 2024 | Allow | 2 | 0 | 0 | No | No |
| 18659338 | PROCESSES FOR THE PREPARATION OF 4-{8-AMINO-3-[(2S)-1-(BUT-2-YNOYL)-PYRROLIDIN-2-YL]IMIDAZO[1,5-a]-PYRAZIN-1-YL}N-(PYRIDIN-2-YL)-BENZAMIDE | May 2024 | July 2025 | Allow | 14 | 0 | 1 | No | No |
| 18656222 | NEUROPROTECTIVE COMPOSITIONS AND METHODS OF USING THE SAME | May 2024 | February 2026 | Allow | 21 | 1 | 1 | No | No |
| 18636634 | Prodigiosin Analogs And Methods Of Use | April 2024 | February 2025 | Allow | 10 | 1 | 0 | Yes | No |
| 18622657 | PROCESSES FOR PREPARING SOLID STATE FORMS | March 2024 | March 2025 | Allow | 11 | 2 | 1 | No | No |
| 18605379 | THYROID HORMONE RECEPTOR AGONISTS AND USES THEREOF | March 2024 | March 2025 | Allow | 12 | 0 | 1 | Yes | No |
| 18594979 | SUBSTITUTED PYRROLIDONES AND PIPERIDONES AS SMALL MOLECULE INHIBITORS OF EZH2 AND EED PROTEIN BINDING | March 2024 | December 2025 | Allow | 21 | 1 | 1 | No | No |
| 18590133 | THIAZOLE TETHERED ORGANOSELENIDES AS 5-LIPOXYGENASE INHIBITORS | February 2024 | April 2024 | Allow | 2 | 0 | 0 | No | No |
| 18442885 | CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF | February 2024 | February 2025 | Allow | 12 | 1 | 0 | No | No |
| 18435082 | SOLID DOSAGE FORM HAVING EXCELLENT STABILITY | February 2024 | June 2025 | Allow | 16 | 1 | 0 | No | No |
| 18427639 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | January 2024 | December 2025 | Abandon | 23 | 2 | 0 | No | No |
| 18422118 | TINOSTAMUSTINE FOR USE IN THE TREATMENT OF T-CELL PROLYMPHOCYTIC LEUKAEMIA | January 2024 | March 2025 | Allow | 14 | 1 | 0 | No | No |
| 18402493 | BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS | January 2024 | November 2024 | Allow | 10 | 1 | 0 | No | No |
| 18395992 | 3-(4-CHLOROPHENYL)-5-{[5-METHYL-2-(PROPAN-2-YL)PHENOXY]METHYL}- 1,2,4-OXADIAZOLE AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUND | December 2023 | April 2024 | Allow | 4 | 0 | 0 | No | No |
| 18396243 | 3-(4-CHLOROPHENYL)-5-{[5-METHYL-2-(PROPAN-2-YL)PHENOXY]METHYL}- 1,2,4-OXADIAZOLE AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUND | December 2023 | March 2024 | Allow | 2 | 0 | 0 | No | No |
| 18394624 | COMPOUNDS | December 2023 | March 2025 | Abandon | 15 | 0 | 1 | No | No |
| 18573305 | AZETIDINYL PYRIMIDINES AND USES THEREOF | December 2023 | March 2026 | Allow | 27 | 0 | 0 | Yes | No |
| 18390780 | COMPOSITIONS FOR TREATING ACNE AND DERMATOLOGICAL CONDITIONS | December 2023 | August 2024 | Allow | 8 | 1 | 1 | No | No |
| 18545558 | SULCARDINE ADMINISTRATION FOR TREATMENT OF ACUTE ATRIAL FIBRILLATION | December 2023 | November 2024 | Allow | 11 | 1 | 0 | No | No |
| 18545458 | SUBSTITUTED 2-AMINOBENZIMIDAZOLES ANALOGS AS ANTIBIOFILM AGENTS | December 2023 | April 2025 | Allow | 16 | 1 | 0 | No | No |
| 18544963 | DIALKYL TRYPTAMINES AND THEIR THERAPEUTIC USES | December 2023 | September 2025 | Abandon | 21 | 0 | 1 | No | No |
| 18539688 | PHARMACEUTICAL INTERMEDIATES AND METHODS FOR PREPARING THE SAME IN THE SYNTHESIS OF MUSCIMOL AND CONGENERS AND DERIVATIVES THEREOF | December 2023 | April 2024 | Allow | 4 | 1 | 1 | No | No |
| 18536542 | Neuroplastogens and Non-Hallucinogenic Serotonin 5-HT2A Receptor Modulators | December 2023 | April 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18531575 | PYRIMIDINE AND PYRIDINE AMINE COMPOUNDS AND USAGE THEREOF IN DISEASE TREATMENT | December 2023 | September 2024 | Allow | 9 | 0 | 0 | No | No |
| 18516458 | DUAL INHIBITORS OF TIM-3 AND PD-1 PATHWAYS | November 2023 | October 2024 | Allow | 11 | 1 | 0 | No | No |
| 18516358 | INHIBITION OF DIPEPTIDE REPEAT PROTEINS | November 2023 | January 2025 | Allow | 14 | 1 | 0 | No | No |
| 18561835 | SYNTHESIS OF N-VINYL COMPOUNDS BY REACTING NH-COMPOUNDS WITH ACETYLENE IN PRESENCE OF HOMOGENEOUS PHOSPHINE CATALYST | November 2023 | June 2024 | Allow | 7 | 0 | 0 | No | No |
| 18481141 | AUTOTAXIN INHIBITOR COMPOUNDS | October 2023 | December 2024 | Allow | 14 | 1 | 0 | No | No |
| 18474522 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALOPECIA AREATA ACTING AS A FUNCTIONAL ANTAGONIST FOR S1PR1 AND S1PR4 | September 2023 | February 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18468636 | PROCESS FOR PREPARING AFICAMTEN | September 2023 | November 2024 | Allow | 14 | 1 | 0 | No | No |
| 18368143 | CRYSTALLINE SALTS OF N-ETHYL-(5-FLUORO-1H-INDOL-3-YL)-N-METHYLETHAN-1-AMINE | September 2023 | February 2024 | Allow | 5 | 0 | 2 | Yes | No |
| 18459944 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | September 2023 | August 2025 | Abandon | 24 | 1 | 1 | No | No |
| 18238713 | 3-(4-CHLOROPHENYL)-5-{[5-METHYL-2-(PROPAN-2-YL)PHENOXY]METHYL}- 1,2,4-OXADIAZOLE AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUND | August 2023 | November 2023 | Allow | 2 | 0 | 1 | No | No |
| 18453887 | PYRROLE COMPOUNDS | August 2023 | November 2025 | Allow | 26 | 1 | 1 | Yes | No |
| 18451757 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | August 2023 | March 2025 | Abandon | 19 | 2 | 0 | No | No |
| 18448495 | METHODS OF INHIBITING TUMOR METASTASIS | August 2023 | March 2025 | Abandon | 19 | 0 | 1 | No | No |
| 18362249 | COMPOUNDS USEFUL AS KINASE INHIBITORS | July 2023 | September 2024 | Allow | 13 | 1 | 0 | No | No |
| 18360976 | METHODS OF TREATING PSYCHOLOGICAL DISORDERS THROUGH THE ADMINISTRATION OF SEROTONIN 5-HT2C RECEPTOR MODULATORS | July 2023 | August 2024 | Allow | 13 | 1 | 0 | No | No |
| 18274093 | PYRAZOLAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | July 2023 | March 2026 | Allow | 31 | 0 | 0 | No | No |
| 18354848 | XANTHOHUMOL DERIVATIVES AND METHODS FOR MAKING AND USING | July 2023 | October 2025 | Allow | 27 | 0 | 0 | No | No |
| 18223169 | THERAPEUTIC COMPOUNDS | July 2023 | November 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18353492 | DEUTERATED TRYPTAMINE DERIVATIVES AND METHODS OF USE | July 2023 | June 2024 | Allow | 11 | 1 | 0 | No | No |
| 18352721 | TREATING PRIMARY OR IDIOPATHIC HYPEROXALURIA WITH SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE | July 2023 | October 2024 | Allow | 15 | 1 | 0 | Yes | No |
| 18343415 | METHYLLACTAM RING COMPOUND AND PHARMACEUTICAL USE THEREOF | June 2023 | April 2025 | Allow | 21 | 0 | 1 | No | No |
| 18258586 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | June 2023 | September 2025 | Allow | 27 | 0 | 0 | No | No |
| 18337313 | MCT4 INHIBITORS FOR TREATING DISEASE | June 2023 | August 2024 | Allow | 14 | 1 | 0 | No | No |
| 18257746 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | June 2023 | September 2025 | Allow | 27 | 0 | 0 | Yes | No |
| 18210330 | PROCESS FOR THE PRODUCTION OF LEVETIRACETAM | June 2023 | November 2025 | Allow | 29 | 0 | 0 | Yes | No |
| 18208633 | PROCESS FOR THE PRODUCTION OF LEVETIRACETAM AND INTERMEDIATES THEREOF | June 2023 | September 2025 | Allow | 28 | 0 | 0 | No | No |
| 18207447 | RADIATION MITIGATOR AND METHOD OF USE THEREOF | June 2023 | November 2024 | Allow | 17 | 1 | 0 | Yes | No |
| 18331779 | PYRAZOLE COMPOUNDS SUBSTITUTED WITH HETEROARYL AND PHARMACEUTICAL USE THEREOF | June 2023 | January 2026 | Allow | 31 | 2 | 1 | No | No |
| 18256570 | DIALKYL TRYPTAMINES AND THEIR THERAPEUTIC USES | June 2023 | February 2025 | Allow | 21 | 2 | 1 | No | No |
| 18201715 | INHIBITORS OF VAP-1 | May 2023 | September 2024 | Allow | 16 | 1 | 1 | No | No |
| 18197615 | NEW FORMULATIONS | May 2023 | July 2024 | Allow | 14 | 1 | 0 | No | No |
| 18316183 | CFTR REGULATORS AND METHODS OF USE THEREOF | May 2023 | March 2024 | Allow | 10 | 1 | 0 | No | No |
| 18140966 | NOVEL PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | April 2023 | February 2024 | Allow | 10 | 1 | 0 | No | No |
| 18306652 | BENZOSELENOPHENE, BENZOTHIOPHENE, AND BENZOFURAN ANALOGS AND METHODS OF MODULATING THE SEROTONIN 5-HT2C RECEPTOR | April 2023 | July 2023 | Allow | 3 | 0 | 0 | No | No |
| 18136016 | HUMAN PLASMA KALLIKREIN INHIBITORS | April 2023 | July 2024 | Allow | 15 | 1 | 0 | No | No |
| 18136025 | HUMAN PLASMA KALLIKREIN INHIBITORS | April 2023 | June 2024 | Allow | 14 | 1 | 0 | No | No |
| 18194609 | CATHEPSIN L INHIBITORS | March 2023 | September 2023 | Allow | 6 | 1 | 0 | No | No |
| 18128850 | REMDESIVIR TREATMENT METHODS | March 2023 | September 2023 | Allow | 6 | 1 | 0 | No | No |
| 18246074 | NOVEL POTASSIUM CHANNEL INHIBITORS | March 2023 | August 2025 | Allow | 29 | 0 | 0 | No | No |
| 18120073 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | March 2023 | January 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18173573 | NEPRILYSIN INHIBITORS | February 2023 | October 2023 | Allow | 8 | 0 | 0 | No | No |
| 18112790 | SILOXANE DERIVATIVES OF AMINO ACIDS HAVING SURFACE-ACTIVE PROPERTIES | February 2023 | August 2025 | Allow | 29 | 0 | 0 | No | No |
| 18166789 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | February 2023 | December 2023 | Allow | 10 | 1 | 0 | No | No |
| 18165037 | COMPOUNDS USEFUL FOR INHIBITING RET KINASE | February 2023 | December 2023 | Allow | 10 | 1 | 0 | No | No |
| 18162398 | METHODS AND COMPOSITIONS FOR TOPICAL DELIVERY OF PROSTAGLANDINS TO SUBCUTANEOUS FAT | January 2023 | February 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18160060 | DEUTERATED COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | January 2023 | January 2024 | Allow | 12 | 1 | 0 | No | No |
| 18006856 | COMPOSITIONS ND METHODS USING SAME FOR GERMANIUM SEED LAYER | January 2023 | September 2025 | Allow | 31 | 1 | 0 | Yes | No |
| 18101014 | BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS | January 2023 | October 2023 | Allow | 9 | 1 | 0 | No | No |
| 18017449 | METHOD FOR PRODUCING A-HYDROXY CARBOXYLIC ACID COMPOSITION | January 2023 | November 2025 | Allow | 34 | 1 | 0 | No | No |
| 18155924 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | January 2023 | July 2024 | Allow | 18 | 2 | 0 | No | No |
| 18097814 | NAPHTHALENE ISOXAZOLINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS | January 2023 | July 2024 | Allow | 18 | 2 | 1 | No | No |
| 18154894 | COMPLEX OF GADOLINIUM AND A CHELATING LIGAND DERIVED FROM A DIASTEREOISOMERICALLY ENRICHED PCTA AND PREPARATION AND PURIFICATION PROCESS | January 2023 | April 2024 | Allow | 15 | 2 | 0 | Yes | No |
| 18153319 | Sphingosine Pathway Modulating Compounds For The Treatment Of Coronavirus Infection | January 2023 | November 2023 | Allow | 10 | 1 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SAEED, KAMAL A.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 40.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner SAEED, KAMAL A works in Art Unit 1626 and has examined 2,607 patent applications in our dataset. With an allowance rate of 85.2%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 21 months.
Examiner SAEED, KAMAL A's allowance rate of 85.2% places them in the 61% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by SAEED, KAMAL A receive 0.77 office actions before reaching final disposition. This places the examiner in the 5% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by SAEED, KAMAL A is 21 months. This places the examiner in the 90% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +3.8% benefit to allowance rate for applications examined by SAEED, KAMAL A. This interview benefit is in the 27% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 45.6% of applications are subsequently allowed. This success rate is in the 96% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 81.0% of cases where such amendments are filed. This entry rate is in the 96% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 92.3% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 83.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 50.8% are granted (fully or in part). This grant rate is in the 50% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 15.4% of allowed cases (in the 97% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.8% of allowed cases (in the 82% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.